Takeda Pharmaceutical Company Limited (NYSE: TAK )’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

(RTTNews) - Takeda (TAK), Tuesday announced that the European Commission has approved ADCETRIS combined with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone for newly ...

European Commission approves Adcetris, Takeda & Pfizer's antibody-drug combo, for frontline Hodgkin lymphoma. Read more here.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

With the exception of the US and Canada, where Pfizer has commercialization rights, Takeda is in charge of Adcetris' worldwide distribution. This decision marks the second approval for an ADCETRIS ...

OSAKA, Japan & CAMBRIDGE, Mass. - Takeda Pharmaceutical Company Limited announced that its therapy, ADCETRIS® (brentuximab vedotin), in combination with a chemotherapy regimen, has been approved ...

NORTHAMPTON, MA / ACCESS Newswire / June 3, 2025 / By Guy Diedrich, Ph.DIn every corner of the globe, digital technology is becoming the bridge to opportunity, empowerment, and transformation. Cisco's ...

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

Brentuximab vedotin (Adcetris, Takeda) is indicated for 'adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and ...